Found 3 matching trials
G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer
PHASE1This was a study to investigate the potential clinical benefit of G1T38 as ...
Location
Beverly Hills Cancer Center
First-in-Human Safety, PK, and Food Effect Study of Single Ascending Doses of G1T38 in Healthy Volunteers
PHASE1This first-in-human (FIH) study will provide the first safety and pharmacok...
Location
PRA Early Development Clinic
G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
PHASE1This is a study to investigate the potential clinical benefit of G1T38 as a...
Location
MHAT for Womens Health - Nadezhda OOD